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The structure of glycogen phosphorylase b with an alkyl-
dihydropyridine-dicarboxylic acid compound, a novel 
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Background:  In muscle and liver, glycogen concentrations are regulated by the
reciprocal activities of glycogen phosphorylase (GP) and glycogen synthase. An
alkyl-dihydropyridine-dicarboxylic acid has been found to be a potent inhibitor of
GP, and as such has potential to contribute to the regulation of glycogen
metabolism in the non-insulin-dependent diabetes diseased state. The inhibitor
has no structural similarity to the natural regulators of GP. We have carried out
structural studies in order to elucidate the mechanism of inhibition.
Results:  Kinetic studies with rabbit muscle glycogen phosphorylase b (GPb)
show that the compound (–)(S)-3-isopropyl 4-(2-chlorophenyl)-1,4-dihydro-1-
ethyl-2-methyl-pyridine-3,5,6-tricarboxylate (Bay W1807) has a Ki = 1.6 nM and
is a competitive inhibitor with respect to AMP. The structure of the
cocrystallised GPb–W1807 complex has been determined at 100K to 2.3 Å
resolution and refined to an R factor of 0.198 (Rfree = 0.287). W1807 binds at
the GPb allosteric effector site, the site which binds AMP, glucose-6-phosphate
and a number of other phosphorylated ligands, and induces conformational
changes that are characteristic of those observed with the naturally occurring
allosteric inhibitor, glucose-6-phosphate. The dihydropyridine-5,6-dicarboxylate
groups mimic the phosphate group of ligands that bind to the allosteric site and
contact three arginine residues.
Conclusions:  The high affinity of W1807 for GP appears to arise from the
numerous nonpolar interactions made between the ligand and the protein. Its
potency as an inhibitor results from the induced conformational changes that
lock the enzyme in a conformation known as the T′ state. Allosteric enzymes,
such as GP, offer a new strategy for structure-based drug design in which the
allosteric site can be exploited. The results reported here may have important
implications in the design of new therapeutic compounds.
Introduction
Glycogen phosphorylase (GP) catalyses the first step in
glycogen degradation to yield glucose-1-phosphate (Glc-1-
P). In muscle, Glc-1-P is utilised via glycolysis to provide
energy to sustain muscle contraction. In the liver, Glc-1-P is
mostly converted by phosphoglucomutase and glucose-6-
phosphatase to glucose which is released for the benefit of
other tissues, especially the central nervous system which
relies on glucose as its major source of fuel. GP is an exem-
plary control enzyme regulated both by reversible phos-
phorylation and by allosteric effectors. Because of its role in
the regulation of glucose output in the liver, there is an
interest in the design of potent phosphorylase inhibitors
that would allow some insights into the different processes
that effect glucose output and which may be of therapeutic
value in the treatment of non-insulin-dependent diabetes.
Output of glucose from the liver is the result of two
processes, glycogenolysis and gluconeogenesis. In the
postabsorptive state, glycogenolysis normally accounts
for more than 70% of the hepatic glucose output, but in
other situations and in the diseased state, output via glu-
coneogenesis may become more important [1]. Insulin
stimulates hepatic cells to transport glucose out of the
bloodstream and to store it within the cell in the form of
glycogen. In the most common form of diabetes, the
non-insulin-dependent diabetes mellitus, cells fail to
respond to insulin either because of insufficient insulin
or because of resistance of the cell receptors to insulin
[2]. Under these conditions the liver continues to output
glucose even though blood glucose levels may already be
high. Compounds that act synergistically with insulin to
facilitate inhibition of hepatic output of glucose and to
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stimulate utilisation of glucose via glycogen synthase are
of pharmaceutical importance.
The 1-alkyl-1,4 dihydropyridine-2,3-dicarboxylic acids
(Figure 1a) have been found to exhibit blood glucose lower-
ing effects in rats [3] and to act via inhibition of glycogen
phosphorylases a (GPa; the phosphorylated form of GP) and
b (GPb; the nonphosphorylated form of GP) (HB et al.,
unpublished results). One of these compounds, (–)(S)-3-
isopropyl 4-(2-chlorophenyl)-1,4-dihydro-1-ethyl-2-methyl-
pyridine-3,5,6-tricarboxylate (Bay W1807, the active
enantiomer of the racemate Bay U6751) is the most potent
inhibitor of GP known to date (Figure 1b). The absolute
configuration of W1807 was determined by X-ray diffrac-
tion using lactic acid as a chiral probe (SG and L Born,
unpublished results). W1807 has little chemical similarity to
any of the known physiological regulatory molecules of
GPb and its likely mode of action was difficult to predict. 
To a first approximation the regulatory properties of 
GP may be explained in terms of the Monod–Wyman–
Changeux hypothesis [4], in which the enzyme is viewed as
existing in equilibrium between two (or at least two) differ-
ent conformational states [5–8]. The T (less active) state is
present in the absence of ligands and its conformation is
promoted by allosteric inhibitors; the R (more active) state
is promoted by substrate and by allosteric effectors includ-
ing phosphorylation. Both GPb and GPa can exist in both
the T and R states depending upon the presence or
absence of inhibitors or activators. The allosteric dimeric
GPb molecule has at least five different recognition sites for
control effectors [9]. In the present work we describe
kinetic studies on GP inhibition by W1807 and X-ray crys-
tallographic binding studies which show that W1807 binds
at the allosteric effector site and induces conformational
changes. These changes are characteristic of the so-called
T′ state conformation of the enzyme, which is also adopted
in the presence of bound glucose-6-phosphate (Glc-6-P), a
naturally occurring inhibitor of GP [10]. The T′ state refers
to the conformation of the GPb–Glc-6 complex structure.
Results and discussion
Kinetic studies of the effects of W1807 on GPb activity
Analysis of Lineweaver–Burk plots at a constant concentra-
tion of Glc-1-P (20 mM) and glycogen (1%), and different
concentrations of W1807 and AMP, showed that W1807
was a competitive inhibitor of GPb with respect to AMP
(data not shown). In the absence of inhibitor the apparent
Km for AMP is 28.6 µM (Hill coefficient of 1.6). IC50 values
for W1807 are 18.9 ± 0.5 nM, 22.7 ± 0.1 nM, 28.5 ± 0.7 nM
and 41.1 ± 3.1 nM in the presence of 10 µM, 20 µM, 40 µM
and 80 µM AMP, respectively. Figure 2 shows the effect of
AMP on the Ki,app for W1807 inhibition of GPb. Analysis of
the data, as described in the figure legend, gave a Ki value
of 1.6 nM assuming that W1807 is competitive with respect
to AMP. Although it is an oversimplification to interpret all
of the GP kinetic results in terms of the Monod–Wyman–
Changeux concerted model for allosteric proteins [4], the
theory does provide a satisfactory explanation for the struc-
tural results. According to the theory, heterotrophic interac-
tions arise from the perturbation of the equilibrium
between the different functional states. An allosteric
inhibitor exhibits considerably greater affinity for the less
active state than the active state and hence favours the less
active state. Under the conditions in which the measure-
ments were made with AMP-activated GPb, the high affin-
ity exhibited by W1807 perturbs the equilibrium almost
exclusively to the inactive state and the Ki effectively repre-
sents the dissociation constant for the inactive state. Con-
version of GPb to GPa through phosphorylation perturbs
the equilibrium towards the active state. The allosteric con-
stant L0 (i.e., the ratio between the concentrations of the
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Figure 1
The chemical structures of (a) 1-alkyl-1,4
dihydropyridine-2,3-dicarboxylic acid and (b)
Bay W1807.
less active T state and active R state in the absence of
ligand) decreases from 3000 for GPb to 3–13 for GPa
(reviewed in [11]). W1807 was found to inhibit R state GPa
in the presence of 1 mM AMP (data not shown) but the
apparent Ki was over a 1000-fold greater than the corre-
sponding Ki for GPb in the presence of AMP. Under these
conditions it may be inferred that the equilibrium for GPa
is more difficult to perturb in favour of the less active state
and the inhibition constant represents an approximate
measure of the affinity for the active state.
Structure of the GPb–W1807 complex
The effector-binding sites on GP are shown in Figure 3a
and summarised in the figure legend. The crystal struc-
ture of the cocrystallised W1807–GPb complex at 2.3 Å
resolution (Table 1) showed that the inhibitor molecule
bound at the allosteric effector site (Figure 3b), consistent
with kinetic observations. The allosteric site is lined by
two α helices, α2 and α8, and a short β strand, β7. The
site is closed by the cap′ region, residues 36′ to 47′, from
the other subunit (where the prime refers to residues
from the other molecule of the dimer). W1807 fits neatly
into the site and the inhibitor exploits numerous contacts
(Figure 4a; Tables 2 and 3; the numbering system for
atoms is shown in Figure 1). The conformation of W1807
is close to that computed by the programme SYBYL and
energy minimised by the TRIPOS force field. The C1
atom is tetrahedral and the plane of the chlorophenyl
ring is oriented almost perpendicular to the plane of the
dihydropyridine ring with the chlorine directed into the
space between the O3B atom of the carboxylic acid and
the O8 ester oxygen atom (Figure 4b). The plane of one
carboxylate group (C13 and oxygens O3A and O3B) is
located approximately in the plane of the dihydropyri-
dine ring and the plane of the other carboxylate (C14 and
oxygens O4A and O4B) is located almost perpendicular
to the dihydropyridine ring. The interactions between
W1807 and GPb are dominated by three major groups of
nonpolar contacts and by charge–charge interactions
between the carboxylate groups and arginine residues. 
The chlorophenyl group is sandwiched between the aro-
matic sidechain of Phe196 and the sidechain of Val45′
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Figure 2
The kinetics of GPb inhibition by W1807 with respect to AMP. Effect
of AMP concentration on the Ki,app for W1807 inhibition of GPb.
Kinetic data (in tetraplicate) obtained with 5 µg/ml GPb at constant
concentrations of Glc-1-P (20 mM), glycogen (1%) and various
concentrations of the activator AMP and inhibitor W1807 were
analysed using Scatchard plots. [I]bound for a given AMP concentration
was calculated by the equation [I]bound = [E]total (Vo–Vi)/Vo, where
[E]total is the total enzyme concentration, Vi is the initial velocity at a
given AMP concentration in the presence of W1807, and Vo is the
initial velocity in the absence of W1807. Ki,app was calculated from the
relationship Ki,app = [E]free[I]free/[I]bound. The Ki,app mean values (together
with the standard deviations of the mean values, n = 4) plotted versus
AMP concentration yielded a curve from which an approximate Ki value
of 1.6 nM can be calculated by extrapolation, assuming that W1807 is
a competitive inhibitor with respect to AMP (Ki,app = Ki (1 + [AMP]/Km)).
Table 1
Statistics of data collection, processing and refinement for the
GPb–W1807 complex.
Cell dimensions (Å)
a, b, c 127.11, 127.11, 115.46
No. of reflections measured 242,759
No. of unique reflections 39,549
Resolution (Å) 30–2.3
Completeness (%) 94.9
(outer shell 2.38–2.30 Å) (%) (95.9)
<I/σ(I)>* 10.5
(outer shell 2.38–2.30 Å) (3.6)
Rm(I) 0.095
(outer shell 2.38–2.30 Å)† (0.382)
No. of reflections used in 37,399
refinement (8.0–2.3 Å, F > 2σ)
No. of protein atoms 6757
No. of waters in final cycle 570
No. of ligand atoms 34
Initial R factor (Rfree) (%)‡ 39.6 (40.3)
Final R factor (Rfree) (%)‡ 0.198 (0.287)
Rms deviation
bond lengths (Å) 0.011
bond angles (°) 1.56
*σ(I) is the standard deviation of I. †Merging Rm is defined as
Rm =ΣiΣh | <Ih> – Iih | / ΣiΣh Iih, where <Ih> and Iih are the mean and the
ith measurement of intensity for reflection h, respectively. ‡The
crystallographic R factor is defined as R = Σ | |Fo | – |Fc | | / Σ|Fo|, where
|Fo| and |Fc| are the observed and calculated structure-factor amplitudes,
respectively. Rfree is the corresponding R value for a randomly chosen
10% of the reflections that were not included in the refinement.
(Figure 4a). The two phenyl rings are inclined at approx-
imately 40° and contacts are made from all atoms of the
chlorophenyl ring to the edge (CE1 and CZ atoms) of
Phe196, representing interactions from the δ– pi electron
cloud of the chlorophenyl ring to the δ+ hydrogen atoms
on the phenylalanine [12]. There is a significant move-
ment of Phe196 (discussed below). The chlorine atom 
of the chlorophenyl group is buried in a pocket where 
it makes several van der Waals interactions to Arg193 
and to Asp227. There are no favourable short contacts
between the carbon-bonded halogen and electronegative
atoms such as those identified by Lommerse et al. [13] in
a survey of small molecule crystal structures. The chlo-
rine appears to assist binding by filling a pocket on the
protein surface.
Nonpolar contacts are augmented by the ethyl group
(C16 and C17) which stacks against Tyr75 making some
seven van der Waals contacts; an example of favourable
interactions between the hydrogens of CH2 and CH3
groups with the pi electrons of an aromatic ring [14]. The
isopropyl group of W1807 (C19, C20 and C21) contacts
Trp67, Ile68 and the aliphatic part of Arg193 (Figure 4a).
Residues Trp67 and Ile68 are located in the middle
portion of the long α2 helix. There is a bend in this helix
around residue 65 and both this region and Tyr75 are sen-
sitive to the binding of activators, such as AMP, to GPb.
In the complex with W1807, there is no conformational
change in this region or in the conformation of Tyr75 and
the residues remain in their T-state conformation.
The carboxylate oxygens of W1807 exploit the allosteric
effector phosphate-recognition site. This site is composed
of two arginine residues located on the α8 helix, Arg309
and Arg310, and a more distant arginine, Arg242. The site
recognises a variety of phosphorylated compounds, such
as AMP, ATP, Glc-6-P, NADH and inorganic phosphate.
In the GPb–W1807 complex Arg309 shifts its sidechain
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Figure 3
A diagram of the GPb dimer molecule viewed down the twofold
symmetry axis and showing the ligand-binding sites. One subunit is
shown in blue and the other is in cyan. The catalytic site is indicated by
the essential cofactor pyridoxal phosphate (PLP; yellow). The catalytic
site is buried at the centre of the subunit accessible to the bulk-solvent
through a 15 Å long channel. (a) The regulatory binding sites. AMP (in
white) is shown at the allosteric effector site. This site also binds the
allosteric inhibitor glucose-6-P (Glc-6-P) and a number of other
phosphorylated compounds and is situated at the subunit–subunit
interface some 30 Å from the catalytic site. Ligands bound at this site
may either activate, by promoting the R state, or inhibit, by promoting
the T state. Caffeine is shown in red at the nucleoside inhibitor site;
occupation of this site stabilises the T state of the enzyme and blocks
access to the catalytic site. Oligosaccharide (in purple) is indicated at
the glycogen storage site. The phosphorylation site, Ser14, is not
shown. (b) The binding site for W1807 (orange) at the allosteric
effector site. (The figure was produced using XOBJECTS, a molecular
illustration package; MEM Noble, unpublished results.)
conformation in order to make the contact to the carboxy-
late, a movement that is also observed on binding phos-
phorylated compounds. In the native GPb structure there
is a network of carboxylate–guanidinium interactions
from Asp227 to Arg242, from to Arg242 to Asp306, and
from Asp306 to Arg310. These interactions are extended
in the inhibitor complex through the carboxyl oxygens
O3A, O3B and O4A to Arg242, Arg309 and Arg310 to
create an extensive charge–charge hydrogen-bond network
of three guanidinium groups and four carboxylic acid
groups (Figure 4b).
On forming the complex with GPb the inhibitor becomes
almost entirely buried. The solvent accessible surface area
is reduced from 602 Å2 in the free state to 43 Å2 in the
bound state, resulting in a surface area of 559 Å2 that
becomes inaccessible to water. Both polar and nonpolar
groups are buried, but the greatest contribution comes
from the nonpolar groups which contribute 420 Å2 (75%) of
the surface that becomes inaccessible. On the protein
surface, a total of 305 Å2 solvent-accessible surface area
becomes inaccessible on binding W1807, of which 220 Å2
(71%) is contributed by nonpolar groups. In total about ten
water molecules, that are present in the native structure,
are displaced on binding W1807: four are displaced by the
carboxylate groups, four by the chlorophenyl group, one by
the methyl group and one by the ester oxygen.
Conformational changes
There is little overall conformational change in tertiary
structure of GPb on cocrystallisation with W1807. The
root mean square (rms) difference in Cα atoms with
respect to native T state GPb is 0.604 Å (or 0.408 Å if
those residues that are mobile with B factors > 60 Å2 are
omitted). At the catalytic site there are no significant dif-
ferences in amino acid sidechain positions. The enzyme
was cocrystallised under conditions that favour the T state
and in the presence of the inhibitor the catalytic site
retains the T state conformation. Glycerol, used as a cry-
oprotectant in the low temperature crystallographic work,
is bound at the catalytic site and makes hydrogen bonds
from its three hydroxyl groups that mimic the hydrogen
bonds made by the O3, O4 and O6 hydroxyl groups of
glucose when bound at this site [15]. 
The major conformational change on binding W1807
occurs in the vicinity of the allosteric effector site
(Figure 5a). The shifts allow the protein to close around
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Figure 4
Details of the contacts between W1807 and
GPb. (a) Stereo diagram showing the
nonpolar contacts from W1807 to Phe196,
Val45′ (from the other subunit), Arg193, and
residues from the α2 helix (Trp67, Ile68 and
Tyr75). The contacts from the carboxylate
groups to Arg242, and to Arg309 and
Arg310 from the α8 helix, are partly obscured
in this view. In this and other figures, carbon,
nitrogen, oxygen and chlorine atoms of
W1807 are shown as orange, blue, red and
green, respectively. For GPb, carbon atoms in
the GPb–W1807 complex are shown in blue
and those from the other subunit are shown in
cyan. (b) Stereo diagram of the details of the
ionic interactions between the W1807
carboxylate groups and Arg242, Arg309 and
Arg310 and the hydrogen bonds (thin lines)
made by the arginines with other carboxylate
groups in the vicinity. (The figure was
produced using XOBJECTS, a molecular
illustration package; MEM Noble, unpublished
results.) 
the irregular shaped inhibitor. The loop, residues 192–196,
shifts (about 1 Å to 1.6 Å in Cα atoms) towards W1807 and
allows Phe196 to contact the inhibitor. Shifts in the
sidechain atoms of Phe196 are as great as 2.9 Å. There is
also a small change in subunit–subunit packing that
results in a displacement of the cap residues so that, for
example, Val45′ shifts about 1.2 Å closer to the other
subunit. This is a result of a global shift between the sub-
units and there is very little change in tertiary structure in
the cap region apart from differences in a few surface
sidechain conformations. The conformational changes
lead to increased contacts between the inhibitor and the
protein. Attempts to diffuse W1807 into preformed crys-
tals of GPb resulted in no observed binding. This observa-
tion suggests that the conformational changes may have
been restricted by the crystal lattice forces and that the
changes, which both tighten the site and alter slightly the
subunit interface about the crystallographic twofold axis,
are important for generating a high-affinity site.
In native GPb there are hydrogen bonds across the
subunit interface in the vicinity of the allosteric site that
are important in maintaining the dimer structure: Arg193
hydrogen bonds to the mainchain oxygens of residues 39′
and 40′ and Glu195 hydrogen bonds to Lys41′. These
contacts are present in both T state and R state GPs. On
forming the complex with W1807, the major shift in
residues 193 to 196 affects the positions of key subunit
interface residues. The intersubunit hydrogen-bonding
pattern, however, is hardly changed (Figure 5a). Arg193
still hydrogen bonds to Val40′ O but the distance to
Leu39′ O is just too far (3.8 Å). Glu195 is still able to
hydrogen bond to Lys41′ because of compensatory shifts.
In the native structure there is a van der Waals contact
from Pro194 to Tyr185′. This contact appears important
because it couples changes at the allosteric interface to
the other subunit interface, the so-called tower–tower′
interface comprising two antiparallel α helices, and con-
nects to the catalytic site [10]. This contact is also
retained in the inhibitor complex as a result of compen-
satory shifts in both Tyr185′ and Pro194.
Comparison with the GPb–Glc-6-P complex
Glc-6-P is the most potent, naturally occurring inhibitor
of GPb. In the resting muscle cell, levels of Glc-6-P are
sufficient to retain the enzyme in the T state and prevent
wasteful glycogen degradation. On activation by elevated
levels of AMP or by phosphorylation, the R state is pro-
moted, Glc-6-P binding is considerably weakened and
glycogen degradation is stimulated [16]. Glc-6-P exhibits
a KD of between 20–70 µM for free GPb [17]. Glc-6-P is
much less effective when competing with AMP and
exhibits a Ki = 300–900 µM [18,19] or in binding to R
state GPa (KD = 1700 µM) [19,20].
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Table 2
Hydrogen bonds in the GPb–W1807 complex at the allosteric
site.
W1807 atom GPb atom Distance (Å)
O3A Arg309 NH2 2.6
Arg310 NH1 3.0
O3B Arg242 NH2 3.2
Wat430* 2.6
O4A Arg309 NH2 2.7
*Wat430 is in turn hydrogen bonded to Gln71 NE2 (bond distance =
3.0 Å).
Table 3
van der Waals interactions in the GPb–W1807 complex at the
allosteric site.
W1807 atom GPb atoms Number of
contacts
C1 Phe196 CE1 1
C2 Phe196 CE1 1
C3 Glu195 OE1; Phe196 CE1, CZ; 4
Lys41′ NZ
C4 Glu195 OE1; Phe196 CE1, CZ; 4
Val45′ CG1
C5 Phe196 CE1, CZ; Val45′ CG2; Wat507 4
C6 Phe196 CZ; Val45′ CG2 2
C7 Wat430 1
C8 Gln71 CB 1
C11 Gln71 CB 1
C13 Phe196 CE1; Arg309 NH2; 4
Arg310 NH1; Wat430
C14 Arg309 NH2; Arg310 CD 2
C15 Gln71 C, O; Gln72 N, CA, CG 5
C17 Tyr75 CB, CG, CD1 3
C18 Gln71 CB 1
C19 Ile68 CA, CB, CG1 3
C20 Ile68 CG1; Arg193 NH2; Val40′ O 3
C21 Trp67 O, CD1; Ile68 CA, CG1; 5
Arg193 NH2
Cl Arg193 CZ, NE, NH2; Asp227 OD1; 6
Arg242 NH2; Wat430
O3A Phe196 CZ, CE1; Arg242 NH1; 5
Arg309 CZ; Arg310 CD
O3B Phe196 CE1; Arg242 CZ, NH1; 4
Arg310 NH1
O4A Arg309 CZ; Arg310 CD, CG 3 
O4B Arg310 CG, CD 2
O8 Gln71 CB, CG 2
The total number of contacts is 67.
Glc-6-P binds at the allosteric effector site and promotes
conformational changes in the T state GPb, leading to the
formation of the T′ state [10]. The phosphate group of Glc-
6-P contacts Arg242, Arg309 and Arg310. Two of the phos-
phate oxygens superimpose on the carboxylate oxygens
O3A and O3B of W1807 (Figure 5b). The glucosyl moiety
of Glc-6-P partially overlaps with the positions of the iso-
propyl group of W1807 but there is no overlap with other
atoms. A very similar shift to that observed on binding
W1807 is observed in region 192–196 of GPb on bind-
ing Glc-6-P (Figure 5b). On Glc-6-P binding, the shift of
Phe196 results in shielding of the phosphate-recognition
site. In the complex with W1807 the shift in Phe196
appears to be directed towards optimising van der Waals
contacts with the chlorophenyl ring, but it also shields the
contacts of the carboxylates with Arg242, Arg309 and
Arg310. The similarity in conformation between the GPb–
W1807 complex and the GPb–Glc-6-P complex charac-
terises the W1807 complex as a T′ state conformation.
Glc-6-P is a relatively polar molecule. Some 73% of the
solvent-accessible area of the free compound is contributed
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Figure 5
Stereo diagrams illustrating binding modes of
different ligands at the GPb allosteric site. (a)
Native T state GPb (carbon atoms yellow) and
the GPb–W1807 complex (carbon atoms of
GPb blue and of W1807 orange). The shifts
in Phe196 and in Val45′ are apparent. (b) The
T′ state GPb–Glc-6-P complex (carbon atoms
green) and GPb–W1807 complex (coloured
as in (a)). The positions of residues 192–196
and residues 41′–46′ from the other subunit
are almost identical in the two complexes. (c)
The R state GPb–AMP complex (carbon
atoms white) and W1807–GPb complex
(coloured as in (a)). The shift of residues
192–196 from the native T state structure is
in the opposite direction to the shift in the
GPb–W1807 complex (compare with Figure
5a). The Phe196 sidechain does not alter its
position, and there is a significant change in
the position of Tyr75 and in residues 35′–45′
from the other subunit. (The figure was
produced using XOBJECTS, a molecular
illustration package; MEM Noble, unpublished
results.)
by polar groups of atoms. On binding to GPb, there is a
total change in the solvent-accessible area of 328 Å2 (92%)
and polar groups contribute 241 Å2 (74%) to this buried
surface. Thus there is a significant difference in the type of
contacts made by Glc-6-P and W1807 at the allosteric site.
Contacts from Glc-6-P to the enzyme are mostly hydrogen-
bond interactions and there are relatively few van der
Waals interactions. In contrast, the contacts from W1807 to
the enzyme are dominated by the substantial nonpolar van
der Waals interactions to Val45′, Trp67, Ile68, Tyr75 and
Phe196 and also by ionic interactions from the carboxylate
groups to the arginine residues. The nonpolar contacts
appear to be the major source of binding energy that
results in an inhibitor with nanomolar affinity observed for
W1807 compared with the micromolar affinity exhibited
by Glc-6-P. The ability of W1807 and Glc-6-P to promote
the movement of the 192–196 loop characterising a T′
state appears to be an important factor in the potency of
both inhibitors. 
Comparison with the GPb–AMP complex in the R state
AMP is the classic allosteric activator of GPb. It binds with
relatively low affinity to the inactive T state form of GPb
(KD greater than 250 µM [21]) and with a much higher
affinity (KD = 3 µM [22]) to the activated R state form.
There are substantial changes in tertiary and quaternary
structure between the T and the R states that alter the
subunit contacts in the vicinity of the AMP allosteric
effector site, the subunit contacts that connect on the
other side of the molecule to the catalytic site, and the
catalytic site itself. Comparison of the T′ state W1807
complex and the R state AMP complex of GPb allows
some of the features to be identified that govern whether
a molecule is an allosteric inhibitor or allosteric activator.
The overall rms difference in Cα coordinates between the
subunits of the T′ state GPb–W1807 complex and the R
state GPb–AMP complex is 1.0 Å (excluding mobile
regions with B factors greater than 60 Å2). This small value
disguises some large local differences that represent the
changes on the T→R transition which result in an increase
in affinity for AMP from several hundred micromolar to a
few micromolar. The phosphate of AMP binds to Arg309
and Arg310 but is displaced slightly from the phosphate
position of Glc-6-P and the corresponding carboxyl group
of W1807 (Figure 5c). The ribose partially overlaps with
the dihydropyridine ring (C8 and C11 atoms) and the
methyl group (C15 atom) of W1807. The adenine occupies
a position which has little overlap with W1807 or Glc-6-P.
In the R state AMP–GPb complex, there is a significant
shift in the sidechain of Tyr75 from its T state position,
which results in van der Waals contacts from the tyrosine to
the adenine (Figure 5c). The loop region 192–196 shifts on
the transition from the T state native GPb structure to the
R state AMP complex (0.8 Å for the Cα atom of Phe196)
but these shifts are in the opposite direction to those
observed for W1807 and Glc-6-P binding. In the cap′
region most of the differences in structure between the
W1807 complex and native T state GPb take place
between residues 43′ and 49′. In contrast, in the AMP
complex most of the differences occur in the region 35′ to
45′ and these shifts are correlated with changes in the α2
helix as part of the allosteric transition. These changes lead
to a closer contact of Val45′ with the AMP ribose.
Examination of the allosteric site in R state GPa (data not
shown) suggests that the site could accommodate W1807
but that the contacts would be less favourable. In particu-
lar, residues 192–196 would be required to shift to provide
the contacts to the chlorophenyl ring but such a shift would
be resisted by the subunit–subunit contacts that promote
the R state. Hence, it would be anticipated that the affinity
of the R state for W1807 would be less than the T state but
the binding mode and conformational changes have to be
confirmed by experimental measurement.
Shape complementarity at the allosteric effector site
The allosteric site exhibits considerable malleability that
allows it to accommodate different ligands for which the
only common features are the utilisation of charge–charge
interactions with arginine residues. The allosteric effector
sites for the native T state GPb, the T′ state GPb–W1807
complex, the T′ state GPb–Glc-6-P complex and the R
state GPb–AMP complex with the solvent-accessible sur-
faces superimposed are shown in Figure 6. The conforma-
tional changes, that accompany binding of W1807, open up
a complementary pocket (right-hand side of figure) that
accommodates the chlorophenyl ring. The dihydropyridine
ring fits the preformed pocket and its substituents also fit
the space available. A similar trend is observed with Glc-6-
P except that the right-hand pocket has not opened as
much as in the W1807 complex and the glucopyranose
moiety does not fully occupy the space available. In the
AMP complex the shift of Tyr75 creates a pocket that
recognises the adenine and the native conformation of
Phe196 blocks the right-hand pocket.
The ability of ligand-binding sites to respond to natu-
rally occurring cellular regulatory metabolites is frequently
observed and confers selective advantage for regulation.
The ability of a site to respond to a nonphysiological
ligand, that has no chemical similarity to naturally occur-
ring ligands, is remarkable but such phenomena are not
unknown. For example, the catalytic site of aldose reduc-
tase can respond in different ways to different synthetic
inhibitors [23]. The site which binds a number of chemi-
cally unrelated non-nucleoside inhibitors in HIV reverse
transcriptase also exhibits a degree of pliability that leads
to a common inhibitory mechanism for these inhibitors
[24]. The tunnel leading to the catalytic site of cyclooxy-
genases exhibits different geometry in different isoforms
that can be exploited for selective binding [25]. In these
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Figure 6
Stereo diagrams of the Connolly molecular
surface in the vicinity of the allosteric effector
site of GPb for the different ligand complexes.
(a) Native T state GPb. (b) The GPb–W1807
complex. (c) The T′ state GPb–Glc-6-P
complex. (d) The R state GPb–AMP complex.
The change in shape of the allosteric effector
site as it accommodates different ligands is
apparent.
and in the present example screening for effective ligand
binding has identified high-affinity ligands that, by
chance, are able to generate conformational changes that
lead to high affinity selective binding. Although such
changes are easy to detect and rationalise in terms of the
crystal structure they are much less easy to predict in a
way that would facilitate structure-based drug design.
Implications for structure-based drug design
There is much current interest in the regulation of signal-
transduction proteins that contain phosphate recognition
sites (e.g. SH2 domains and protein kinases) to control
processes such as cell growth and inflammation. The
present work has shown that under some conditions a
phosphate group can be satisfactorily mimicked by dihy-
dropyridine-5,6-dicarboxylic acid groups. The allosteric
phosphate-recognition site in GPb contains two adjacent
arginines and one more distant arginine. This cluster of
basic residues is typical of many phosphate-recognition
sites in other proteins which exhibit tight phosphate associ-
ation. The ability of a single carboxylic acid group to recog-
nise the three arginine phosphate-recognition site has not
been tested. In general, a single carboxyl group is a poor
mimic of a phosphate group, especially where conforma-
tional changes are also involved in the recognition [26].
The origins of the high potency of W1807 for GPb
(Ki = 1.6 nM) appear to lie both in the numerous nonpolar
contacts made between the ligand and the protein and also
in the induced conformational changes that lock the
enzyme in its inactive T′ conformation. On formation of the
inhibitor–protein complex there is a total decrease in
solvent-accessible area (protein plus ligand) of 864 Å2, of
which 640 Å2 is contributed by nonpolar groups. There is
both a favourable entropic gain as the nonpolar groups are
transferred from the bulk-solvent and a favourable
enthalpic gain arising from van der Waals interactions, espe-
cially a significant number of CH–pi electron interactions.
Glucose is a natural regulator of GP activity in the liver and
acts both as a competitive inhibitor and as an allosteric
inhibitor that promotes the T state inactive form of the
enzyme and makes GPa a better substrate for the inactivat-
ing phosphatase. In a programme that aimed to exploit this
property, we have designed and synthesised a number of
glucose analogue inhibitors and have shown that these do
indeed have the desired properties of more potent inactiva-
tion of GP than glucose. These compounds effectively
inhibit GP in hepatocytes and activate GP phosphatase
activity [27–29]. Glucose, however, is a relatively polar mol-
ecule and binds with a Ki in the order of 1–2 mM, despite
numerous polar contacts made to the enzyme. The best
inhibitor, a spirohydantoin glucopyranose [29], exhibited a
1000-fold improvement with a Ki = 3 µM and it has proved
difficult to improve on this with further modifications. The
cost of transferring the polar glucose molecule from the
bulk-solvent to the buried site in the enzyme, located 15 Å
from the surface, evidently provides a high energetic barrier
that is difficult to overcome.
The catalytic site of enzymes has been the target for much
structure-based drug design where the specificity engi-
neered by substrate recognition and possible transition state
analogue geometry can be exploited. Binding at alternative
sites has also proved productive and has involved sites that
either block access or cause conformational changes at the
catalytic site. Allosteric enzymes offer an additional strat-
egy, whereby the allosteric site can be exploited to shift the
equilibrium in favour of the inactive T state conformation.
The present studies have focused on rabbit muscle GP
whose regulation by metabolic effectors is well understood.
Liver GP has 80% identity with the mammalian muscle
isoform but, although it exhibits similar binding constants
for allosteric effectors, it is much more sluggish in its
response. This observation suggests that the allosteric com-
munication between the effector site and the catalytic site
is less well coupled in the liver enzyme than in the muscle
enzyme [30]. The details of the kinetics and interactions of
W1807 with the liver isoform remain to be established. For
the treatment of disease there is often an advantage in a
ligand that is selective for tissue type either by uptake or by
selective action on different isoforms.
Biological implications
Type II diabetes is characterised by chronic hyper-
glycaemia and insulin resistance. Treatment to prevent
the damaging fluctuations in glucose levels centre
around lifestyle changes, treatment with compounds
that promote insulin secretion, such as sulphonylurea-
related compounds, and injection of insulin. There is a
continued interest in new agents that may contribute 
to the regulation of blood glucose levels in the diseased
state. In muscle and liver, glycogen phosphorylase plays
an important role in regulation of glycogen metabolism.
In the liver, glucose output arises from glycogenolysis
and from gluconeogenesis, of which the greater amount
in the normal postabsorptive state is from glycogenolysis.
As part of a screening process, alkyl-dihydropyridine-
dicarboxylic acids were identified as potent inhibitors of
glycogen phosphorylase that were effective in lowering
blood glucose levels in rats. The present kinetic studies
show that one of these compounds, (–)(S)-3-isopropyl 4-
(2-chlorophenyl)-1,4-dihydro-1-ethyl-2-methyl-pyridine-
3,5,6-tricarboxylate (Bay W1807), has a Ki = 1.6 nM for
rabbit muscle glycogen phosphorylase b, making it the
most potent phosphorylase inhibitor known to date.
Crystallographic binding studies show that W1807
exerts its effects by binding at the allosteric effector 
site of glycogen phosphorylase, the site that binds the
allosteric activator AMP and the allosteric inhibitor,
glucose-6-phosphate. The phosphate-recognition site
utilised by these effectors is recognised by the
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dihydropyridine-5,6-dicarboxylic acid groups of the
inhibitor. The structure provides an example of specific
phosphate site recognition by non-phosphate groups,
that may have implications for drug design of other
phosphoregulatory proteins. The high affinity appears
to arise from numerous nonpolar interactions made
between the ligand and protein, especially those
between CH groups and pi electron orbitals of aromatic
rings. On formation of the complex, a total of 864 Å2
solvent-accessible surface becomes inaccessible of
which 74% is from nonpolar groups. The allosteric
effector site at which W1807 binds is over 30 Å from
the catalytic site and the inhibition of catalysis is
mediated by conformational changes that lock the
protein in an inactive T′ conformation. The conforma-
tional changes induced on binding W1807 are almost
identical to those that accompany the binding of the
allosteric inhibitor, glucose-6-phosphate. The ability of
nonphysiological ligands to tailor binding sites is not
uncommon but in this case the non-physiological ligand
mimics the effects of the naturally occurring allosteric
inhibitor, although there is no chemical similarity
between the two. Exploitation of this result to design
new therapeutic compounds remains to be explored.
Materials and methods
Kinetics
GPb was isolated from rabbit skeletal muscle as previously described
[20]. AMP, Glc-1-P (dipotassium salt), glycogen, and other chemicals
were obtained from Sigma Chemical Company. Oyster glycogen was
freed from AMP by the method of Helmreich and Cori [31]. Initial
reaction rates were measured at pH 6.8 and 30°C in the direction of
glycogen synthesis by the release of orthophosphate from Glc-1-P.
The enzyme (5 µg/ml) was assayed in 50 mM triethanolamine
hydrochloride, pH 6.8, 100 mM KCl, 1 mM dithiothreitol (DTT), 1%
glycogen, and various concentrations of Glc-1-P, AMP, and inhibitor as
indicated in Figure 2. The enzyme was preincubated with glycogen for
15 min at 30°C before the reaction was started by adding Glc-1-P.
Samples were withdrawn at 1 min intervals over the period from
1–5 min and transferred into 0.2% sodium dodecyl sulphate (SDS) to
stop the reaction. Inorganic phosphate released in the GP reaction
was determined and initial reaction rates calculated from the pseudo-
first order reaction constants as described [32]. Kinetic data were
analysed by the use of the nonlinear regression program GraFit [33].
Calculations of GPb molarity were based on a MW of 97,834.
Crystallisation and data collection
GPb was cocrystallised with 1 mM W1807 in a medium consisting of
27–28 mg/ml enzyme, 1 mM spermine, 3 mM DTT, 10 mM Bes,
0.1 mM EDTA, and 0.02% sodium azide, pH 6.7 (16°C). Crystals were
grown within a few days. Prior to data collection, the crystals were
transferred to fresh buffer solution (10 mM Bes, 0.1 mM EDTA, 0.02%
sodium azide, pH 6.7) containing 30% v/v glycerol for 30–60 sec prior
to flash freezing (100K). Diffraction data were collected from a single
crystal on the beamline X11 at Hamburg (X-ray λ = 0.928 Å) using an
18 cm MAR Research Image Plate detector. The crystal to image plate
distance was 210 mm and gave a maximum resolution of 2.3 Å at the
edge of the detector. Data frames of 1.0° oscillation angle were col-
lected over a total angular range of 49°. Integration and data reduction
were performed with the programmes DENZO and SCALEPACK [34].
The unit cell of the frozen crystals was a = b = 127.11 Å, c = 115.46 Å
which gives a small decrease in volume of 3% compared with the
native enzyme at room temperature.
Structure refinement
Refinement of the GPb–W1807 complex was performed with XPLOR
[35]. The starting protein structure was the 2.3 Å refined structure of the
T state GPb–glucose complex [15] comprising residues 14–842 and
539 water molecules and with glucose removed. The initial steps of the
refinement comprised rigid-body refinement (15 steps), least squares
conjugate gradient refinement (100 cycles, tolerance 0.05 Å) and
restrained individual B-factor refinement (35 cycles, target standard devi-
ations of 1.5 Å2 for 1–2 atom pairs and 2.0 Å2 for angle atom pairs).
These steps were followed by simulated annealing (heating the structure
to 1000K, and cooling to 300K with a time step of 0.25 fs and a total
time 0.7 ps) and further positional refinement and resulted in a drop in R
factor from an initial 39.6% to 21.8%. At this stage difference Fourier
maps were calculated with SIGMAA [36] weighted (Fo–Fc) and (2Fo–Fc)
coefficients and the structure was analysed with the programme O [37].
Using PEAKMAX (from the CCP4 suite of programmes [38]), the (Fo–Fc)
map was searched for peaks greater than 3.5σ. The difference density
indicated binding of W1807 at the allosteric site and glycerol binding at
the catalytic site. The maps also indicated that the sidechain of Arg309
had shifted into the allosteric site in order to contact the carboxyl groups
of the inhibitor. Models of W1807 and glycerol, generated using the
programme SYBYL (Tripos Associates Inc. (1992) SYBYL Molecular
Modelling Software, St Louis, Missouri, USA) and with partial charges
estimated from AM1 calculations using MOPAC [39] (total charge for
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Figure 7
Stereo view of the electron density calculated
with coefficients 2Fo–Fc and calculated
phases for the final refined model and
contoured at 1σ. The refined coordinates of
the GP–W1807 structure are superimposed;
the carbon atoms of W1807 are shown in
orange and those of GP in blue.
W1807 = –2.0), were fitted to the density at the allosteric and catalytic
sites, respectively. The positions of further water molecules were deter-
mined and the peaks screened for likely hydrogen bonds. A total of 31
new water molecules were added to the model making a total of 570
waters. Several sidechains and some mainchain atoms were adjusted
and refinement continued with simulated annealing (heating the structure
to 1000K and cooling to 300K with a time step of 0.25 fs and a total time
0.7 ps) further conjugate gradient minimisation (40 cycles), overall B-
factor refinement (15 cycles) and restrained B-factor refinement (20
cycles) to give an R value of 19.8 %. The free R value, used as a statisti-
cal cross-validation diagnostic for assessing improvement during refine-
ment, fell to 28.7 %, a value which is not inconsistent with values found
at this resolution for other proteins [40], especially when there are
regions of disorder. The average B factors for mainchain atoms,
sidechain atoms, pyridoxal phosphate, W1807, glycerol and water mol-
ecules were 24, 25, 14, 18, 20 and 35 Å2, respectively. Residues where
B-factor values exceeded 60 Å2 included 211, 251–260, 314–325,
550–556 and 831–842. These regions are also poorly ordered in the
native structure [41]. Part of the final 2Fo–Fc electron-density map is
shown in Figure 7.
The structure was analysed and hydrogen bonds were assigned if the
distance between electronegative atoms was less than 3.3 Å and if
both angles between these atoms and the preceding atoms were
greater than 90°. van der Waals contacts were noted for nonhydrogen
atoms separated by less than 4 Å. Superposition of structures was per-
formed with the least squares option in O [35]. Solvent accessibility
calculations were carried out with the programme MSP [42] using the
Lee and Richards algorithm. ‘Nonpolar’ atoms were defined as carbon
and sulphur and ‘polar’ atoms as nitrogen and oxygen.
Accession numbers
Coordinates have been submitted to the protein data bank with acces-
sion number 1AMV.
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